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Zusammenfassung
Hintergrund: Während der Lymphknotenstatus in der 
Axilla weiterhin einer der wichtigsten Prognosefaktoren 
beim Mammakarzinom ist, hat sich die Sentinel-Lymph-
knoten-Biopsie (sentinel lymph node biopsy, SLNB) zu 
einer der Hauptmethoden zur weitreichenden Reduktion 
der postoperativen Morbidität und Verbesserung der 
kurz- und langfristigen Lebensqualität entwickelt. Mate-
rial und Methoden: Zwischen 1996 und 2010 wurden an 
unserer Institution 18 884 SLNBs bei Mammakarzinom-
patientinnen durchgeführt und damit die Validität und 
der positive Einfluss der Methode auf die Lebensqualität 
der Patienten bestätigt, obgleich Entscheidungsvor-
gänge zur adjuvanten Therapie stark von biologischen 
Eigenschaften des jeweiligen Tumors abhängig sind. 
Ergebnisse: Der vorliegende Artikel fasst publizierte 
Daten zusammen, die hauptsächlich an unserer Institu-
tion gesammelt wurden, unter Einbeziehung spezifischer 
klinischer Szenarien wie duktale intraepitheliale Neopla-
sien, intramammäre Sentinel-Knoten, multizentrische 
Mamma kar zinome, vorherige Brustoperationen, vorhe-
rige ästhetische Operationen an der Brust, zweite axilläre 
SLNB, schwangere Patientinnen, primäre Chemothera-
pie und männliche Patienten. Schlussfolgerungen: Wir 
sind der Überzeugung, dass SLNB die Standardmethode 
für das Axillastaging in praktisch allen klinischen Situa-
tionen ist, einschließlich derer, die in der Vergangenheit 
als Kontraindikationen für SLNB galten. Die einzige mo-
mentane Kontraindikation ist das Vorliegen von doku-
mentierten Axillametastasen.
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Summary
Background: While axillary nodal status is still one of the 
most important prognostic factors in breast cancer, sen-
tinel lymph node biopsy (SLNB) has evolved as a main 
procedure to strongly reduce postsurgical morbidity 
improving early and long-term quality of life. Material 
and Methods: Between 1996 and 2010, we performed 
18,884 SLNBs for breast cancer, successfully confirming 
the validity of this technique and its positive impact on 
patients’ quality of life, even though decision-making 
processes for adjuvant treatment strongly depend on 
biological features. Results: This paper summarizes pub-
lished data mainly collected in our institute considering 
special clinical scenarios such as ductal intraepithelial 
neoplasia, intramammary sentinel nodes, multicentric 
breast cancer, prior breast surgery, previous breast aes-
thetic surgery, second axillary SLNB, pregnant patients, 
primary chemotherapy, and male patients. Conclusions: 
In general, we believe that SLNB represents the standard 
procedure for axillary staging in virtually all clinical situ-
ations, even in those which were previously considered 
a contraindication for this procedure. At the moment, the 
only contraindication to SLNB is the presence of docu-
mented axillary metastases.
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are doubtful, the mirror sections are immunostained for cytokeratin, 
using a rapid method involving monoclonal anti-cytokeratine antibody 
(DAKO, Copenhagen, Denmark) [6–8].
Findings and Discussion
Long-Term Observation
The 10-year follow-up results of a prospective randomized 
controlled study were recently published [1]. In this trial, we 
enrolled 516 patients with T1 primary breast cancer. A group 
of patients who underwent SLNB plus immediate complete 
axillary dissection was compared with a group who underwent 
axillary dissection just in case of SLN metastasis. The cumula-
tive incidence of axillary metastasis in the SLN group was 
lower than expected (2 of 259 patients) (fig. 1). Overall 
survival was similar between the 2 groups of patients.
We recently reported the outcome of a large cohort of 
patients with a negative SLNB [6]. A total of 3,548 patients 
treated from 1996 to 2004 with negative SLN, who did not re-
ceive axillary dissection, were followed for up to 11 years with 
a median follow-up of 48 months. Among these 3,548 patients, 
the 5-year cumulative incidence was 10.1% (95% confidence 
interval (CI) 8.9–11.3%) with a median time to recurrence of 
29 months. In all these patients, axillary dissection was per-
formed. The cumulative incidence of axillary metastasis at 
5 years was 1.0% (95% CI 0.6–1.4%), significantly lower than 
what was expected under the assumption that approximately 
5–6% of non-sentinel axillary nodes would be positive and 
would become clinically evident occurring at a constant rate 
over a 12-year time interval (fig. 2).
Ductal Intraepithelial Neoplasia
Axillary staging in breast ‘in situ’ pathology is still a matter of 
debate despite the fact that by definition, it is not possible for 
ductal intraepithelial neoplasia (DIN) or ductal carcinoma in 
situ (DCIS) to metastasize either to distant organs or to loco-
regional lymph nodes, as they lack the invasive component. 
Nevertheless, a minimal rate of axillary involvement is com-
monly described in patients with intraductal neoplasia as well. 
SLNB represents a good opportunity, for selected cases, to 
stage patients with a preoperative diagnosis of intraductal ne-
oplasia [9].
Intra et al. [10] in 2008 reported a series of 854 selected 
patients affected by truly pure DCIS, who received lympho-
scintigraphy and SLNB. SLN metastases were detected in 12 
of the 854 patients (1.4%) and isolated tumor cells (ITC) were 
identified in 4 additional patients. 
The risk of node metastasis does not seem to be correlated 
with sub-histotype, necrosis, nuclear grade, hormone receptor 
status, Her2/neu status, KI-67, multifocality, or type of sur-
Introduction
While axillary nodal status is still one of the most important 
prognostic factors in breast cancer, sentinel lymph node 
biopsy (SLNB) has evolved as a main procedure to strongly 
reduce postsurgical morbidity improving early and long-term 
quality of life. Moreover, the decision-making process for 
adjuvant treatment based on axillary status is still important 
but so far this choice is becoming increasingly dependent on 
biological features rather than on the risk of recurrence in 
terms of selecting the treatment having the highest probability 
of response. This vision imposes the necessity to reduce the 
indication of complete axillary dissection as much as possible, 
especially whenever the axilla is clinically negative. At the 
European Institute of Oncology (IEO) in Milan, between 
1996 and 2010, we performed 18,884 SLNBs for breast cancer, 
successfully confirming the validity of this technique and its 
positive impact on patients’ quality of life. In this paper, we 
summarize published data mainly collected in our institute 
concerning SLNB and its application in special clinical 
scenarios.
Material and Methods
Patients
Between 1996 and 2010, 18,884 SLNBs for breast cancer were carried out 
at the IEO in Milan.
Lymphoscintigraphy and SLNB
Lymphoscintigraphy was performed in all cases using our standard tech-
nique previously described [1–3]. Five to 10 MBq of technetium-99m- 
labeled particles (50–200 nm) of human colloidal albumin (Nanocoll, GE 
Healthcare, Milan, Italy) in 0.2 ml saline is injected close to the tumor [4, 
5] or in a subcutaneous projection area. From 15–30 min after radiotracer 
injection, anterior and anterior-oblique lymphoscintigraphic projections 
of the breast and axilla are then obtained to precisely locate the sentinel 
lymph node (SLN). SLNB is performed 4–20 h after radioactive tracer 
injection. A gamma ray-detecting probe in a sterile glove is used to iden-
tify the ‘hot’ SLN and assist in its removal during surgery. During breast 
conservative surgery, if the tumor is in the upper-outer breast quadrant, 
the breast incision is extended to the SLN in the axilla using the probe as 
guide. In other cases, generally, a separate incision for SLNB is necessary. 
SLNB is also performed during total or nipple-sparing mastectomy, in 
these cases, through the same surgical cavity. All SLNs removed are sent 
for intraoperative extensive frozen-section analysis.
Pathology
Pathological examination of the SLN is routinely performed with a com-
plete and extensive intraoperative analysis, without any portion of nodal 
tissue left for fixation and paraffin-embedding. This analysis requires 
30–45 min and is very demanding in terms of time, experience, and 
human resources. However, it allows a complete and final answer to be 
obtained directly during surgery, thereby avoiding the risk of a second 
operation in case an involvement of the SLN is found after an initially 
negative intraoperative report. Any one of the SLN is cut into 60 sections 
(30 pairs), cut at 50 ?m intervals. Whenever residual tissue is left, addi-
tional pairs of sections are cut at 100 ?m intervals. One section of each 
pair is routinely stained with hematoxylin and eosin (H and E). If results 
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sions. The argument lies in whether or not a positive in-
traMSN imposes the necessity for an axillary dissection or 
whether it can be spared [12, 13].
Between December 2001 and September 2006, 9,632 pa-
tient records in the IEO database were retrospectively re-
viewed by Intra et al. [14]. In 22 patients (0.2%), an intraMSN 
in association with the axillary SLN was documented. The in-
traMSN was not identified at surgery in 4 cases, and in 3 cases 
the surgeon decided not to excise it. In the remaining 15 cases, 
both the axillary SLN and the intraMSNs were simultaneously 
excised. Positive intraMSNs were found in 6 patients, 3 of 
which were micrometastatic. In 9 patients, the intraMSN was 
negative. The axillary SLNB proved to be negative in all 
15 patients. Two cases with positive intraMSNs and 1 case 
with a negative intraMSN underwent axillary dissection, and 
all axillary nodes were negative. After 24 months, no axillary 
relapse was identified.
We concluded that when both intraMSNs and axillary SLN 
are present, then both should be biopsied but axillary dissec-
tion should be based solely on the status of the axillary SLN. 
Our routine policy is that a positive intraMSN with negative 
axillary SLN does not justify axillary dissection. When lym-
phoscintigraphy reveals a ‘hot’ intraMSN, we recommend that 
it be sought and removed if technically feasible, in order to 
have an additional prognostic factor and to have better local 
control. Frozen section may be avoided, however, as it does 
not change the axillary surgical approach.
Multicentric Breast Cancer
Several studies have been published showing the success rate, 
sensitivity, negative predictive value, and accuracy of SLNB 
gery. Only age (younger than 50), clinical presentation (mass 
on screening or palpable lesion), and tumor size (median size 
30 mm) seem to be important in predicting the risk of locore-
gional metastasis.Therefore, SLNB should not be considered 
a standard procedure in the treatment of all patients with in-
traductal neoplasia. If the diagnosis is sufficiently guaranteed, 
regardless of the histology, tumor grade, age, clinical presen-
tation, and tumor size, SLNB should be avoided. This hap-
pens when the lesion is completely excised by surgery, or to-
tally removed by core needle biopsy or vacuum assisted 
biopsy. 
The sole criteria for proposing SLNB in patients with a 
preoperative diagnosis of intraductal neoplasia should be un-
certainty regarding the presence of invasive foci at the final 
histological examination. This happens in cases where the 
lesion is not completely excised by conservative surgery (posi-
tive margins of resection or residual microcalcifications at 
postoperative mammogram), or in large solid tumors, or dif-
fuse or pluricentric microcalcifications not macroscopically 
removed by vacuum-assisted biopsy. In such cases, the risk of 
invasion at the final histological examination is related to the 
tumor size, and ranges from 10 to 20% [11]. Whenever mas-
tectomy is required, in our opinion, SLNB is strongly recom-
mended in order to avoid the risk of a second operation.
Intramammary Sentinel Node
The presence of intramammary sentinel nodes (intraMSNs) 
on preoperative lymphoscintigraphy is becoming a more com-
mon finding in the clinical setting. There is no consensus in 
the international literature on how to interpret information 
provided by an intraMSN biopsy when making surgical deci-
Fig. 1. Observed (gray line) and expected (red line) axillary metastasis 
over time in patients with negative sentinel node [1]. Expected cumula-
tive incidence of axillary metastasis in SN group patients who did not 
receive AD, assuming that approximately 5% of non-sentinel axillary 
lymph nodes are metastatic, that all metastatic nodes become clinically 
evident, and do so at a constant rate over the 10-year follow-up.
Fig. 2. Development of axillary metastasis (n = 31) in 3,548 women with 
sentinel node-negative breast cancer [6].
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Second Axillary Sentinel Node Biopsy
Between January 2000 and October 2006, 65 patients showing 
an invasive ipsilateral breast tumor recurrence without 
palpable axillary nodes were offered a second SLNB [21]. 
47 women had invasive carcinoma and 18 DCIS at primary 
surgery. In 63 patients, preoperative lymphoscintigraphy 
showed at least 1 new axillary SLN (identification rate 97%). 
In 5 of these 63, in association with the axillary SLN, extra-
axillary drainage was documented: supraclavicular in 1 patient 
and internal mammary in 4 patients. After a median follow-up 
of 45 months, there were no axillary recurrences in any of the 
57 patients who did not have complete axillary dissection. It is 
difficult to quantify the minimum required interval between 
the first and second SLNB since the time of effective restora-
tion of the lymphatic drainage anatomy is unknown. Never-
theless, a very early breast recurrence is probably residual 
disease rather than true recurrence. In these patients, the first 
SLNB maintains the same predictive value for both the first 
tumor and the early recurrence, and a second SLNB might 
not be indicated. In that series, 6 months was considered 
the minimum interval necessary from the first SLNB before 
proposing a second one. Regardless of whether radiotherapy 
was carried out or not, the SLN identification rate remained 
high (97%).
Pregnant Patients
A previous simulation study [22] demonstrated that the dose 
of radiation to the fetus is minimal during lymphoscintigra-
phy. Currently, we also offer SLNB to women with breast 
cancer diagnosed during pregnancy since a review of the dosi-
metric evaluations reported in the literature as well as our 
data from a simulation study show evidence that the risks to 
the fetus are negligible. Between April 2001 and September 
2007 [23], we managed 45 patients with breast cancer 
diagnosed during pregnancy, who were entered into our dedi-
cated database. Only 12 patients were candidates for SLNB. 
The 12 pregnancies resulted in 11 babies with normal weight 
according to the gestational age and no malformation, who 
were all born after uncomplicated pregnancies. One baby, 
who was born at the 34th week by means of caesarean section, 
was operated on at the age of 3 months for cardiac failure due 
to a perimembranous subaortic ventricular septal defect 
(VSD). However, the VSD was suspected at the morphologi-
cal ultrasound scan which was performed during the 21st week 
of gestation, and lymphoscintigraphy was performed during 
the 26th week. A subsequent a posteriori evaluation by a dif-
ferent observer performed on video material confirmed the 
suspicion of a VSD. After a median follow-up of 32 months 
(range 6–83 months), all the babies were doing well at the 
time of follow-up. No overt axillary lymph node reappearance 
of the disease had occurred in patients with negative nodes. 
in multicentric breast cancer being similar to those in unifocal 
breast cancer [15, 16]. In 2006, Gentilini et al. [17] published a 
report of 42 patients with multicentric breast cancer submit-
ted to SLNB and axillary dissection performed just in case of 
nodal metastasis. 25 patients underwent a single subareolar 
injection, double peritumoral/subdermal injection was ad-
ministered in 17 patients. The identification rate was 100%. 
The mean number of SLN identified was similar in patients 
who received single or double injections. In this study, no 
overt axillary recurrence occurred after a median follow-up 
of 24 months. At our institute, we routinely perform SLNB in 
patients with multicentric disease and a clinically negative 
axilla, in most cases by using a single subareolar injection of 
radiotracer. In some circumstances, when 2 peripheric tumors 
are present, a double peritumoral injection can also be con-
sidered in order to rule out extra-axillary drainage. We al-
ways recommend a careful intraoperative exploration of the 
axilla in order to decrease the risk of false-negative SLN 
findings.
Prior Breast Surgery
From June 1997 to January 2004, 543 patients underwent a 
?????? biopsy [18]. These patients received SLNB by lympho-
scintigraphy performed subdermally on the previously af-
fected area between the scar and the ??????. The SLN was 
identified in 99% of cases. In 70% of cases, the SLN was neg-
ative. Among the 161 patients with positive SLN, this was the 
only positive node in 61.5% of cases. After a median follow-
up of 2 years, 4 nodal recurrences were observed and were 
treated with axillary dissection. In our opinion, SLNB is feasi-
ble and is routinely performed after previous conservative 
surgery and can be considered even after total mastectomy 
[19]. 
Previous Breast Aesthetic Surgery
Between April 2001 and June 2007, 70 patients with previous 
breast aesthetic surgery underwent SLNB. 50 had a previous 
breast augmentation and 20 had breast reduction mammo-
plasty [20]. Lymphoscintigraphy identified the SLN in all 
70 patients (100%). Overall, 72 SLN were identified since 
1 patient underwent a bilateral lymphoscintigraphy for a 
bilateral tumor and 1 patient showed bilateral axillary drain-
age and drainage to the ipsilateral internal mammary chain. 
Forty-nine patients (65%) had negative SLN. Two patients 
(3%) had isolated tumor cells; 23 patients (32%) had a posi-
tive SLN, 5 of which had micrometastasis only. After a 
median follow-up of 19 months, no axillary recurrences 
were observed. We concluded that independent of the pre-
vious surgical approach, a history of aesthetic surgery is not 
a contraindication for SLNB.
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Male Patients
Between April 1999 and January 2005, 75 men with breast 
cancer were treated at the European Institute of Oncology. 
Forty-three patients had a contraindication of clinically posi-
tive axillary nodes. A retrospective analysis of the remaining 
32 patients with clinically negative axillary lymph nodes, who 
had had an SLNB, was carried out [29]. Lymphoscintigraphy 
and subsequent imaging successfully identified axillary hot 
spots in all patients with a mean number of 1.3 (range 1–2). 
The SLN was identified in all patients, and a total of 48 nodes 
were removed, with a mean number of 1.5 SLN per patient 
(range 1–3). 26 patients had negative SLN. Metastases were 
found in 4 patients, and micrometastases were found in the 
remaining 2 patients. After a median follow-up of 30 months 
(range 1–63), no events related to breast cancer or to overt 
axillary reappearance of the tumor occurred during this 
period.
Conclusions
SLNB has become the standard approach for axillary staging 
in patients with breast cancer worldwide. This procedure 
yields the same staging power as axillary lymph node dissec-
tion with less complications and better quality of life [30]. 
This less invasive procedure is possible for several reasons: 
i) Removal of lymph nodes is performed for staging purposes 
and not with curative intent [31–33], therefore, the well-
known risk of having a false-negative result can be accepted 
and comprehended; ii) even if the false-negative risk can be 
generally quantified in about 6%, the occurrence of overt ax-
illary lymph node metastases after a negative SLNB has been 
shown to be lower than expected, being 0.9% after a median 
follow-up of 48 months in a cohort of 3,548 patients [6]; iii) to 
date, the impact of the prognostic information of axillary 
lymph node status in the decision-making process is less im-
portant than in the past as the adjuvant treatment is becoming 
increasingly tailored towards the biological features of the 
disease rather than the risk of recurrence.
The introduction of SLNB represented a revolution and 
one of the latest innovations on the path of minimizing the 
surgical approach to breast cancer patients. As it is a functional 
concept rather than an anatomical entity, SLNB can be applied 
also to special clinical scenarios in which lymphatic drainage 
might be different than under physiologic conditions.
As previously mentioned, we also have to bear in mind that 
lymph node surgery is not curative in itself and has the aim of 
improving regional control of the disease and of achieving 
prognostic information. From this standpoint, the future evo-
lution of lymph node surgery will probably be in the direction 
of further reduction since medical treatment will be more tai-
lored in accordance with tumor biology rather than recurrence 
risk, especially when better diagnostic tools become available.
As in any medical procedure, the decision must take into 
consideration the overall risk-benefit balance. Although cau-
tion is always recommended in any technique involving radia-
tion – the protection of the baby being the major concern – we 
believe that the results available in the literature provide suf-
ficient evidence to exclude any reasonable risk to the fetus 
from SLNB by using our standard technique. Further optimi-
zation can be obtained by lowering the time interval between 
injection and surgery (e.g. 2–4 h), allowing lower activity to be 
injected (e.g. 3–5 MBq) and shorter exposure from the radio-
activity trapped in the tumor.
Primary Chemotherapy
Primary chemotherapy for operable breast cancer is adminis-
tered to reduce primary tumor extent in order to enhance the 
possibility of breast conservative surgery and, no less impor-
tant, to evaluate the ‘in vivo’ response to chemotherapeutic 
drugs. Several studies have questioned the feasibility of SLNB 
in patients treated with preoperative chemotherapy, the main 
concern being that the accuracy of the technique after chemo-
therapy treatment might be diminished with an increase in the 
false-negative rate. On the other hand, many studies have 
demonstrated that the identification and false-negative rates 
of SLNB are similar to those reported in the absence of pre-
operative chemotherapy [24, 25]. In one of the largest studies 
on this topic (National Surgical Adjuvant Breast and Bowel 
Project multicentric trial B-27) [26], there were non-signifi-
cant differences in false-negative rate according to clinical pa-
tient and tumor characteristics, method of lymphatic map-
ping, or tumor response to chemotherapy. A meta-analysis 
concerning SLNB after preoperative chemotherapy was pub-
lished including 21 papers for a total of 1,273 patients [27]. 
The identification rate ranged from 72 to 100%, with a pooled 
estimate of 90%. The sensitivity of SLNB ranged from 67 to 
100%, with a pooled estimate of 88%. These results are com-
parable to those obtained from multicenter studies evaluating 
SLNB before systemic therapy and suggest that SLNB is ap-
plicable following neo-adjuvant chemotherapy. Therefore, in 
women with a clinically negative axilla before the start of neo-
adjuvant chemotherapy, SLNB might be considered after the 
completion of medical treatment if no progression has 
occurred. 
In patients with suspicious axillary nodes at presentation 
which have been ‘downstaged’ to N0 by medical treatment, 
SLNB might also be considered an option after proper diag-
nostic preoperative evaluation. SLNB is obviously not recom-
mended for patients whose axillary nodes remain clinically 
suspicious after chemotherapy. Positron emission tomography 
(PET) scan might be a useful tool for properly selecting those 
patients in whom SLNB can be performed, even though this 
still represents a matter of research [28].
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situations even in those which were previously considered a 
contraindication for this procedure. Basically, our policy is to 
perform SLNB always unless documented axillary metastases 
are present.
Acknowledgement
The authors are greatly thankful to AIRC (Associazione Italiana pel la 
Ricerca contro il Cancro) who supported the clinical research on SLNB. 
The authors also wish to thank Mr. William Russell-Edu for his help with 
the English language.
Disclosure Statement
The authors deny any sponsorship or funding arrangement and have no 
conflicts of interests to declare.
A recent publication with data taken from the first 566 pa-
tients with positive SLN of the AMAROS trial [34] did not 
find any significant differences in terms of administration of 
adjuvant systemic therapy. The authors concluded that the 
absence of knowledge regarding the extent of nodal involve-
ment in the axillary radiation therapy (ART) arm appeared to 
have no major impact on the administration of adjuvant treat-
ment. The findings of the American College of Surgeons 
Oncology Group Z0011 trial push ahead the field of contro-
versy [34]. In fact, in this trial, which compared axillary clear-
ance with observation in patients with SLN involvement, out-
come appeared identical in the 2 groups in terms of overall 
survival, disease-free survival, and axillary recurrence. Those 
arguments are in favor of minimizing axillary surgery.
Based on all these considerations, we do not believe that 
it is necessary to validate SLNB in advance in every special 
clinical setting, and we apply SLND virtually in all clinical 
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